Vycor Medical, Inc. (VYCO) Q3 Revenue Falls 19% to $414.9K

Vycor Medical, Inc. (VYCO) reported a 19% year-over-year decline in Q3 2026 revenue to $414.9K, with nine-month revenue down 11% to $1.3M. GAAP net losses were $161.4K for Q3 and $325.8K for the nine-month period, though prior-period net loss figures were not provided.

Original reporting
Published Nov 13, 2026, 4:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 4:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Vycor Medical, Inc. (VYCO) Q3 Revenue Falls 19% to $414.9K — source image
Decision brief

The 30-second read

$VYCOBearishLow
01

Why it matters

The earnings miss underscores ongoing revenue contraction, which may trigger short‑selling or defensive positioning by traders.

02

Market read

The earnings release provides new, material data for VYCO, but the small scale limits broader market impact.

03

What to watch

Potential pipeline of product approvals or undisclosed cost‑cutting measures not reflected in this brief release.

Relevance 6/10Novelty 6/10Timing: post‑market release today

Background

Vycor Medical, Inc. is a small medical‑device company that filed its Q3 2026 earnings release on TradingView.

Company-level read

Ticker impact

$VYCOBearishHigh confidence
Context

Q3 2026 revenue fell 19% YoY to $414.9K and nine‑month revenue fell 11% to $1.3M, with GAAP net losses of $161.4K and $325.8K.

Expected impact

likely downward pressure as investors digest the shrinking top line and losses

Evidence & confidence

The company posted a material revenue drop and larger net loss versus the prior period, a fresh earnings disclosure for a micro‑cap.

Market effects

Signals weakness in the niche medical‑device segment for small‑cap firms.

Limited to U.S. micro‑cap investors; no broader regional effect.

Minimal global relevance.

Counterpoint

If the company can secure new contracts or a strategic partnership, the stock may rebound despite the current decline.

Key entities

  • Vycor Medical, Inc.

    Micro‑cap medical‑device firm reporting Q3 2026 results.

Related articles

$VYCOMed

Vycor Medical Releases Financial Results for the Three And Nine Months Ended September 30, 2026

VYCOR MEDICAL INC (VYCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Nine Months Ended September 30, 2026 BOCA RATON, FL (November 13, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and nine months ended September 30, 2026.

$VYCOMed

Vycor Medical Releases Financial Results for the Three And Six Months Ended June 30, 2026

VYCOR MEDICAL INC (VYCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Six Months Ended June 30, 2026 BOCA RATON, FL (August 14, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and six months ended June 30, 2026. The Company op